ABSTRACT
Background Adolescents (ages 10-19) affected by tuberculosis (TB) face unique challenges to completing TB treatment, resulting in increased loss to follow-up and mortality as compared to younger children and older adults. Digital adherence technologies (DATs) may be a useful tool for TB treatment monitoring. In this study we aimed to assess whether 99DOTS, a low-cost DAT, could improve treatment outcomes among adolescents with pulmonary TB (PTB).
Methods We conducted an interrupted time series (ITS) analysis of adolescents initiating treatment for drug susceptible PTB between August 1, 2019 and June 30, 2021 at 30 health facilities in Uganda. ITS analysis was used to model the change in TB treatment outcomes and loss to follow-up in adolescents prior to and after the implementation of a 99DOTS-based intervention. Immediate (level) and trend (slope) changes in outcomes were assessed according to intention-to-treat (ITT) and per protocol (PP) principles.
Findings 630 adolescents were included in the ITT analysis. In the post-intervention period, 78.4% of adolescents were enrolled on 99DOTS. The proportion successfully completing TB treatment was 92.4% (303/328) in the post-intervention period and 87.4% (264/302) in the pre-intervention period. In the adjusted ITT analysis, the proportion treated successfully increased (level change, PR 1.18 95% CI 1.08-1.28) and the proportion lost to follow-up decreased (level change, PR 0.93, 95% CI 0.88-0.98) in the immediate post-intervention period. Both proportions remained similar throughout the post-intervention period (p-value for slope change >0.05).
Interpretation There was a high uptake of 99DOTS among adolescents with TB, and use of 99DOTS was associated with improved treatment outcomes. DATs should be further explored as a promising adolescent-specific tool for improving treatment outcomes among adolescents with TB.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
PACTR201808609844917
Funding Statement
The Government of Canada The Bill and Melinda Gates Foundation The United States Agency for International Development via the TB REACH initiative of the Stop TB Partnership
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was approved by institutional review boards at Makerere University School of Public Health and the University of California San Francisco, and by the Uganda National Council for Science and Technology.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
